
Download Complimentary Report Summary
Pharmaceutical Mergers and Acquisitions guides you to build an M&A plan that focuses on key goals, avoids costly mistakes, and realizes deal potential as quickly as possible. CEI designed this study to identify the primary drivers of M&A activity. Through the input of pharma industry leaders, our study provides solutions to the greatest M&A pitfalls and gives clear, detailed insight of trends in pharmaceutical deals. The result: a roadmap to the M&A landscape.
The past year has been marked by heightened M&A activity among companies of all sizes. Small companies are increasingly investing in large-molecule products that are expensive to produce and test in clinical trials - but in this tough economic climate, they face diminishing capital and the threat of closing. To continue their work on time-sensitive compounds, they are exploring the possibility of a company sale. On the other hand, for those companies with cash, this situation presents an opportunity to acquire attractive compounds and technology platforms at a discount.
Timelines, rankings, strategies, and deal profiles will allow you to maximize the benefits and growth opportunities of a deal:
Understand the M&A environment
Learn what is driving the acquisition strategies of top companies - and how other organizations are seeking suitors for their own sales.
Build a competitive deal-making process
Complete the integration as soon as possible -- and boost productivity
Learn from the recent past
We've vetted the top 75 deals of 2009 to determine purchasing trends, including:
Look into the future of M&A
Gather perspectives and predictions on future deals from the managers who execute them.
Compare your deal to others
Call Adam Bianchi at 919-403-6583 to get your own copy of "Pharmaceutical Mergers and Acquisitions" today.